Introduction
Osteoporosis, characterized by reduced bone strength and bone loss, is highly prevalent in aging westernized societies, and adversely affects the health of the elderly people by causing fragility fractures. 1, 2 Diabetes mellitus (DM), a metabolic disease with also increasing prevalence throughout the world, occurs frequently in the elderly, coexisting with osteoporosis. 3 Chronic complications induced by DM adversely affect multiple organs, including bone, and cause an enormous medical and economic burden. 4 In both type 1 and 2 DM, bone structure is altered, associated with an increased fracture risk, delayed fracture healing and potential fracture nonunion. 5 Moreover, a growing body of research shows that type 2 DM increases the fracture risk independent of factors such as bone mineral density and age, currently used for predicting fractures. 6 It has been hypothesized that DM-associated alterations in the skeleton might be added to those related to aging, further increasing bone fragility in diabetic old patients. In this scenario, the development of suitable approaches to improve fracture healing in these subjects is likely to have a great socioeconomic impact.
Strategies to promote bone healing after fractures include providing cell precursors, growth factors, nutrients and/or synthetic materials to the injured area to induce tissue regeneration and replace bone tissue damage. 7 Materials mimicking the bone mineral composition, including biodegradable gelatinglutaraldehyde-coated hydroxyapatite foams (HA-Gel) with attractive properties for application in bone such as osteointegration and osteoconduction, have been used in bone tissue engineering. 8 Adsorption of a diversity of factors to these materials to be used as implants has proved to improve their osteoinductive capacity. 9 Parathyroid hormone (PTH)-related protein (PTHrP) is now emerging as an attractive cytokine in this respect. PTHrP contains a N-terminal 1-37 region with high homology to PTH and a C-terminal region -containing the highly conserved 107-111 sequence, named osteostatin for its anti-bone resorption activity 10 -, displaying osteogenic features both in vitro and in vivo. 11 Interestingly in this regard, systemic administration of N-or C-terminal PTHrP peptides has been reported to reverse at least in part the alterations in bone structure and/or osteoblast differentiation and function in a well characterized type 1 DM mouse model and in Igf1-null mice. [12] [13] [14] Moreover, we previously showed that osteostatin coating onto various implant types of ceramics or even porous titaniums accelerates healing of critical and non-critical bone defects in the long bones of adult rabbits and rats. 15, 16 These observations prompted us to evaluate and compare the efficacy of different PTHrP peptides to promote bone regeneration in a combined aging and DM scenario using a well characterized diabetic model. We used degradable HA-Gel foams as a template for PTHrP or PTHrP (107-111) delivery in a cortical bone defect performed in aging rats with or without concomitant DM . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Materials and methods

Preparation of HA-Gel foams
Tridimensional macroporous HA-Gel foams have been synthesized in a one-step process, using the sol-gel technique for preparing nanocrystalline HA, including a non-ionic surfactant in the synthesis, Pluronic F127
(EO 106 PO 70 EO 106 ), as macropore former in the accelerated evaporation induced self assembly (EISA) method as described elsewhere. 17 Briefly, HA was synthesized from the reaction of calcium nitrate tetrahydrate and triethylphosphite (TIP; Aldrich, Steinheim, Germany), using a molar ratio of F127:TIP of 11. The resulting foams were coated by immersion in a 1.2% (w/v) type A gelatin crosslinked with 0.05% w/v glutaraldehyde solution and then lyophilized for 24 h. 13 The final foams ( Supplementary Fig. 1 ) were characterized by Hg porosimetry in an AutoPore III porosimeter (Micromeritics Instrument Corporation, USA), scanning electron microscopy (SEM) in a JEOL 6400 microscope (Tokyo, Japan) and X-ray diffraction (XRD) in a Philips X'Pert diffractometer using Cu Ka radiation. Characterization details of this material have been previously reported.
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HA-Gel foams were loaded with either PTHrP (1-37) or PTHrP (107-111) (Bachem, Bubendorf, Switzerland) by soaking in a solution of each peptide (at 100 nM) in phosphate-buffered saline, pH 7.4 (PBS) under stirring for 24 h in the cold room. 13 Peptide uptake and release from these materials was determined by measuring absorbance at 280 nm of remaining peptide in the saline solution at different times. By using this method, the mean uptake of Fig. 1A-C) . All aged rats -made diabetic or not-were of the same age (18-20 months old) and weight (Fig. 1D ) by the time of the study as described below.
A group of adult rats aged 6 months was used as younger controls of the old group of rats in order to confirm the age-related bone deterioration. Intact femora from the younger and aged rats were dehydrated and embedded in Goldner's trichrome for light microscopy examination of the distal metaphysis. 15 Old diabetic rats showed less bone volume per total tissue volume ratio [bone volume (BV) over total volume (TV)] and lower trabecular thickness than the old control and the young group of rats, and decreased trabecular separation and trabecular number than the younger group (Table 1) .
Animal housing and care protocols were approved by the Animal Use
Committee of the IIS-Fundación Jiménez Díaz, following the European Union guidelines to decrease pain and suffering of the animals. Our protocol using a limited number of rats (n = 5-10 per experimental group) complied with the 3R
("replace, reduce, and refine") experimental design recommendation.
Rat model of bone healing
Experimental details of the procedure to generate a transcortical defect in the proximal rat tibia have been recently reported. 12, 15 In brief, aged rats with or without DM were anaesthetized with intramuscular injection of 25 mg/kg ketamine and 10 mg/Kg xylazine. A hole of 2 mm diameter was then drilled through the cortex, using continuous washing with saline, in both proximal tibial metaphysis. The left and right tibial defect received the unloaded and PTHrPloaded material, respectively, in each rat. Four weeks post-surgery, a period that has been proved insufficient for complete bone regeneration after the same surgical procedure in young rats, 15 the animals were euthanized using an overdose of ketamine and xylazine, and the long bones were removed and kept frozen at -20ºC until processing. 
Bone histology and µ-computerized tomography (µCT) analysis
The tibial defects were scanned using GE eXplore Locus µCT scanner (GE Healthcare, London, Canada). Image acquisition was performed at 80 kV and 450 µA, collecting 400 projections in one full rotation of the gantry. The resulting raw data were reconstructed using a filtered back-projection algorithm to a final image with a resolution of 93 µm in all three spatial dimensions. Cubic regions corresponding to cortical or trabecular peri-implant areas with a voxel size of 46 µm in all length, width and height were cropped as the region of interest (ROI).
The reconstructed images corresponding to these ROI were viewed and analyzed 
Real time PCR
Total RNA was isolated from the healing rat tibial area with Trizol (Life Technologies, Carlsbad, CA). Gene expression was analyzed by real time PCR using an ABI PRISM 7500 system (Applied Biosystems, Grand Island, NY), as reported. 15, 20 Real time PCR was done using SYBR premix ex Taq (Takara, Otsu, Japan) and the following rat Sost specific primers: 5´- 
Changes in bone structure and histology
Here, we used an experimental rat model showing that a diabetic status, as shown in Fig.1 , aggravates the bone structure deterioration related to aging (Table 1) . We evaluated the osteoinductive capacity of each PTHrP peptide tested as coated onto a degradable implant to heal a transcortical bone injury in this model. Four weeks following implantation of the unloaded foams, incomplete repair of the bone defect was observed in aged rats, an effect more dramatic in those with DM, as shown by 2D (Fig. 2 ) and 3D (frontal and sagittal views) (Fig. 3) µCT images. Furthermore, in the diabetic aged rats, the regenerating tibial defect containing the unloaded material showed structural changes including a decrease in cortical BV/TV and cortical thickness but increased cortical BS/BV (Fig. 4) , as well as decreased trabecular BV/TV and an increase in both trabecular BS/BV and trabecular separation (Fig. 5 ), compared to non-diabetic aged controls. In contrast, rats implanted with PTHrP
(1-37) or PTHrP (107-111)-loaded foams showed complete healing of the defect in both groups of rats, as depicted by µCT images (Fig. 2 and 3 ), accompanied by reversal of the aforementioned changes in bone structure parameters (Fig. 4 and 5).
Consistent with these results, histological assessment of the regenerating bone defect area showed abundant newly formed bone tissue around the osteointegrated HA-Gel foam, associated with the implant containing each
PTHrP peptide, at the time period evaluated (Fig. 6 ). 
Changes in gene expression
We also assessed the expression of various osteoblastic genes in the tibial defect during bone regeneration following 4 weeks of biomaterials implantation in both groups of aged rats. Each type of PTHrP-containing foam in these animals was found to induce overexpression of osteocalcin (a late osteoblast differentiation marker) and VEGF (a key angiogenic factor) in the regenerating area (Fig. 7) . In addition, the expression of Sost -the gene encoding sclerostin, an important inhibitor of the Wnt pathway with a paramount role as a regulator of bone turnover 21 -was increased in the diabetic rats during bone repair; but decreased dramatically by the presence of each PTHrP peptide in the implant in aged rats independently of the diabetic status (Fig. 7) .
Discussion
In the present study, we evaluated the ability of two PTHrP-derived peptides to heal a transcortical defect in rats with two prevalent conditionsaging and DM-which are prone to skeletal fractures. We show that both peptides tested locally delivered at the injury site were similarly efficient to regenerate this noncritical defect in the tibia of old rats independently of their diabetic status.
In humans over 30-35 years of age, bone mineral density and content starts to decrease, and with further aging, structural changes in bone, including cortical bone volume and trabecular number reduction, trabecular spacing increase and cortical bone thinning become manifest. 22 Several factors during aging have been proposed to promote these changes including an increase of reactive oxygen species, bone cell senescence induced by shortage of 3 is also related to poor bone quality in close relationship with the accumulation of advanced glycosylated end-products (AGEs). 24 Even though types 1 and 2 DM affect bone differently, 25 both types have been associated to increased fracture risk due to reduced bone formation. 26, 27 Impaired bone filling of a noncritical defect created at the femoral midshaft was recently observed in obese adult Zucker rats with insulin resistance. 28 In agreement with these observations, our results show that DM worsens the healing of a bone defect generated in the tibial metaphysis of aged rats, as
shown by histological and gene expression evaluation in the bone injury area.
Several mechanisms have been proposed to be responsible for these observations such as high glucose-induced deleterious actions on osteoblasts through glycation and oxidation. 24, 29 Current anabolic therapies to prevent osteoporotic fractures prevalent in aging subjects are based on intermittent s.c. administration of PTH-derived peptides. 30, 31 More recently, PTH (1-34) has been further evaluated in various bone repair animal models. 32 The same type of systemic PTH administration as used to increase bone accrual improved endochondral and intramembranous bone regeneration -as occurs after bone fractures and cortical bone injury, respectively-by targeting various stages of bone regeneration. Daily injection of a high dose of PTH (1-34) (200 µg/Kg) enhanced callus formation following a tibial fracture in old rats. 33 Of note, a lower (75 µg/kg) dose of PTH (1-34) per day induced bone regeneration of subcritical femoral defect in type 2 diabetic rats, although less efficiently than in nondiabetic controls. 28 In addition, daily s.c. injections of a PTHrP analogue based Our present results show that local delivery of PTHrP (1-37) or PTHrP ceramic foam as the one used here as carrier 15 -, PTHrP (1-37) was also rapidly released from the material into the surrounding medium. Assuming similar release kinetics for each PTHrP peptide in our in vivo setting, no significant amount of each peptide is likely to remain in the implant after 5 days; supporting the current idea that an initial burst of each PTHrP peptide might be sufficient to improve bone healing. 15, 16 PTHrP acts as a pivotal endogenous stimulator of bone formation through autocrine, paracrine and even intracrine actions on committed osteoblast precursors enhancing their differentiation and reducing osteoblast apoptosis. 36 For PTHrP to play such predominant role on osteoblast differentiation and survival, control mechanisms must exist to ensure that only short-lived, high levels of PTHrP are available to local targets, since persistently increased local PTHrP levels -as occurs for PTH in hyperparathyroid patientswould favor increased osteoclastogenesis. 11 Interestingly, in this regard, PTHrP haploinsufficiency has been shown to impair healing of a mid-femur fracture in mice. 37 Our results support the validity of a strategy based on the local delivery of the PTHrP peptides tested to promote bone regeneration in the setting of DM-and age-related osteopenia.
Conclusions
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